Development of mycobacterial growth inhibition assays for the early evaluation and gating of novel TB vaccine candidates
<p>Tuberculosis poses a serious global health threat, with an estimated 9 million new cases and 1.5 million deaths annually. The current vaccine, BCG, is inadequate but development of an effective alternative is severely hampered by the lack of an immune correlate of protection. Candidate vacc...
Autor principal: | Tanner, R |
---|---|
Outros Autores: | McShane, H |
Formato: | Thesis |
Idioma: | English |
Publicado em: |
2015
|
Assuntos: |
Registos relacionados
-
A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
Por: Pepponi, I, et al.
Publicado em: (2017) -
Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
Por: Rachel Tanner, et al.
Publicado em: (2020-01-01) -
In vitro Mycobacterial Growth Inhibition in South Korean Adults With Latent TB Infection
Por: Hyejon Lee, et al.
Publicado em: (2019-04-01) -
Mycobacterial glycoproteins: a novel subset of vaccine candidates
Por: Antonio eFacciuolo, et al.
Publicado em: (2014-09-01) -
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
Por: Tanner, R, et al.
Publicado em: (2021)